IRulya Therapeutics Inc.

Report Phase 2b data for LAM-001 in pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Deadline not yet reached (521 days left)

Announced: 9 Oct 2026
Due: 31 Mar 2028

Deadline
Met
Late
Not met
Today

What the company said

“The Company recently initiated a Phase 2b trial in PH-ILD, and data are anticipated in the first quarter of 2028.”

SourceQuince Therapeutics, Inc. Form 8-K press release, 2026-10-09
FilingSEC filing index
Deadline as statedin the first quarter of 2028
Deadline used31 Mar 2028, the last day of the stated period
TypeProject
Permanent referenceKI-C-2026-QNCX-005924
Cite as https://keptindex.org/c/KI-C-2026-QNCX-005924/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Mar 2028.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: Phase 2b trial data for LAM-001 in PH-ILD
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: Medium

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Quince Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-QNCX-005924 · Corrections policy